Patent search cpc:"C07D295/135" Page 1

1.

发明公开
N-SUBSTITUTED C6 CYCLYL CARBOXAMIDE COMPOUNDS AND USES THEREOF 审中-公开

公开(公告)号：US20240360075A1

公开(公告)日：2024-10-31

申请号：US18640931

申请日：2024-04-19

Applicant: ALCON INC.

Inventor： Heeren M. Gordhan , Mitchell A. deLong , Jill M. Sturdivant , David Archer Ellis , Cynthia L. Lichorowic

IPC: C07C233/60 , A61K9/00 , A61K31/16 , A61K31/165 , A61K31/167 , A61K31/175 , A61K31/192 , A61K31/27 , A61K31/277 , A61K31/337 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/4465 , A61K31/495 , A61K31/5375 , A61K31/69 , A61K47/12 , A61K47/18 , A61K47/38 , C07C231/02 , C07C233/58 , C07C233/59 , C07C233/62 , C07C233/63 , C07C235/14 , C07C235/56 , C07C237/24 , C07C271/20 , C07C271/24 , C07C279/22 , C07C315/04 , C07C317/30 , C07D205/04 , C07D207/09 , C07D209/54 , C07D211/58 , C07D213/75 , C07D213/79 , C07D231/40 , C07D239/42 , C07D263/04 , C07D263/56 , C07D265/36 , C07D275/03 , C07D277/46 , C07D295/088 , C07D295/135 , C07D295/32 , C07D305/06 , C07D305/08 , C07D305/14 , C07D307/22 , C07D307/94 , C07D309/14 , C07D311/58 , C07D335/02 , C07F5/02

CPC classification number: C07C233/60 , A61K9/0048 , A61K31/16 , A61K31/165 , A61K31/167 , A61K31/175 , A61K31/192 , A61K31/27 , A61K31/277 , A61K31/337 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/4465 , A61K31/495 , A61K31/5375 , A61K31/69 , A61K47/12 , A61K47/183 , A61K47/186 , A61K47/38 , C07C231/02 , C07C233/58 , C07C233/59 , C07C233/62 , C07C233/63 , C07C235/14 , C07C235/56 , C07C237/24 , C07C271/20 , C07C271/24 , C07C279/22 , C07C315/04 , C07C317/30 , C07D205/04 , C07D207/09 , C07D209/54 , C07D211/58 , C07D213/75 , C07D213/79 , C07D231/40 , C07D239/42 , C07D263/04 , C07D263/56 , C07D265/36 , C07D275/03 , C07D277/46 , C07D295/088 , C07D295/135 , C07D295/32 , C07D305/06 , C07D305/08 , C07D305/14 , C07D307/22 , C07D307/94 , C07D309/14 , C07D311/58 , C07D335/02 , C07F5/025 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/18 , C07C2602/38 , C07C2602/42 , C07C2602/50

Abstract: Described herein are modified monoterpene TRPM8 activating compounds. In particular, provided herein are compounds that affect the function of ion channels in a cell, and are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth, such as cancers.

2.

发明授权
Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof 有权

公开(公告)号：US12060339B2

公开(公告)日：2024-08-13

申请号：US17631212

申请日：2021-07-28

Applicant: Vivozon Inc.

Inventor： Dae Kyu Choi , Hyo Jin Kim , Mi Seon Bae , Jin Choi , Hyun Jin Heo , Yong Seok Lee , Geon Ho Lee , Mi Yon Shim , Jin Sun Park , Han Mi Lee

IPC: C07D295/135 , A61P25/04 , C07C233/66 , C07C233/70 , C07C233/72 , C07C233/78 , C07C233/86 , C07C237/34 , C07D213/40 , C07D213/56 , C07D305/06 , C07D307/14 , C07D309/06 , C07D309/14 , C07D319/12

CPC classification number: C07D295/135 , A61P25/04 , C07C233/66 , C07C233/70 , C07C233/72 , C07C233/78 , C07C233/86 , C07C237/34 , C07D213/40 , C07D213/56 , C07D305/06 , C07D307/14 , C07D309/06 , C07D309/14 , C07D319/12

Abstract: Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.

3.

发明公开
TRPM8 AGONISTS AS COOLING AGENTS AND FOR THE TREATMENT OF DISEASE 审中-公开

公开(公告)号：US20240199564A1

公开(公告)日：2024-06-20

申请号：US18546560

申请日：2022-02-16

Applicant: Concentric Analgesics, Inc.

Inventor： Craig HUSFELD

IPC: C07D295/135 , A61K31/166 , A61K31/40 , A61K31/4465 , A61K31/451 , A61K31/472 , A61K31/4965 , A61K31/5375 , C07C233/62 , C07C235/10 , C07C237/10 , C07D211/46 , C07D213/40 , C07D217/02 , C07D295/185

CPC classification number: C07D295/135 , A61K31/166 , A61K31/40 , A61K31/4465 , A61K31/451 , A61K31/472 , A61K31/4965 , A61K31/5375 , C07C233/62 , C07C235/10 , C07C237/10 , C07D211/46 , C07D213/40 , C07D217/02 , C07D295/185 , C07C2601/16

Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential melastatin 8 receptor (TRPM8) activity.

4.

发明授权
Modulators of HSD17B13 and methods of use thereof 有权

公开(公告)号：US11957687B2

公开(公告)日：2024-04-16

申请号：US17622454

申请日：2020-07-01

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Joseph Vacca

IPC: A61K31/5377 , A61K31/4412 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61P1/16 , C07D213/82 , C07D239/36 , C07D239/56 , C07D295/135 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D498/04 , C07D513/04

CPC classification number: A61K31/5377 , A61K31/4412 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61P1/16 , C07D213/82 , C07D239/36 , C07D239/56 , C07D295/135 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D498/04 , C07D513/04

Abstract: The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

5.

发明授权
Substituted benzamides 有权

公开(公告)号：US11697636B2

公开(公告)日：2023-07-11

申请号：US17096438

申请日：2020-11-12

Applicant: Hoffmann-La Roche Inc.

Inventor： Katrin Groebke Zbinden , Roger Norcross , Phillippe Pfileger

IPC: C07D207/09 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D263/32 , C07D265/30 , C07D267/08 , C07D267/10 , C07D295/135 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K9/20 , C07D495/04

CPC classification number: C07D207/09 , A61K9/2018 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D263/32 , C07D265/30 , C07D267/08 , C07D267/10 , C07D295/135 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04

Abstract: The invention relates to compounds of formula

wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof.

Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

6.

发明公开
N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS 审中-公开

公开(公告)号：US20230146507A1

公开(公告)日：2023-05-11

申请号：US17913490

申请日：2021-03-23

Applicant: Helmholtz-Zentrum Für Infektionsforschung GmbH

Inventor： Rolf W. Hartmann , Jelena Konstantinovic , Jörg Haupenthal , Anna K. Hirsch , Andreas M. Kany , Cansu Kaya , Samir Yahiaoui , Thomas Wichelhaus , Eugen Proschak

IPC: A61K31/196 , A61K31/407 , C07C323/41 , C07C311/08 , C07C311/46 , C07C311/58 , C07C311/64 , C07D295/26 , C07D295/135 , A61K31/18 , A61K31/167 , A61K31/245 , A61K31/64 , A61K31/5375 , A61K31/495 , A61P31/04

CPC classification number: A61K31/196 , A61K31/407 , C07C323/41 , C07C311/08 , C07C311/46 , C07C311/58 , C07C311/64 , C07D295/26 , C07D295/135 , A61K31/18 , A61K31/167 , A61K31/245 , A61K31/64 , A61K31/5375 , A61K31/495 , A61P31/04

Abstract: The present invention related to novel inhibitors of metallo-β3-lactamases of formula (I)

wherein R1 is an optionally substituted aryl group of an optionally substituted heteroaryl group, and the use thereof in the treatment of bacterial infections, especially in combination with β-lactam antibiotics.

7.

发明申请
METHOD AND CATALYST FOR PREPARING ANILINE COMPOUNDS AND USE THEREOF 审中-公开

公开(公告)号：US20190100486A1

公开(公告)日：2019-04-04

申请号：US16142369

申请日：2018-09-26

Applicant: Seasons Biotechnology (Taizhou) Co., Ltd.

Inventor： Qiang JIA , Chi MA , Tianhua MA , Zhengwei YANG

IPC: C07C209/36 , C07C213/02 , C07C319/20 , C07C253/30 , C07D295/135 , B01J21/18 , B01J23/28

CPC classification number: C07C209/36 , B01J21/18 , B01J23/28 , C07C209/365 , C07C213/02 , C07C253/30 , C07C319/20 , C07D295/135 , C07C211/46 , C07C211/47 , C07C211/52 , C07C217/84 , C07C323/37 , C07C255/58 , C07C255/59

Abstract: The present invention provides a method for preparing aniline compounds, and also provides a kind of catalyst and use thereof. This method for synthesizing an aniline compound in the invention includes following steps: use molybdenum oxide and activated carbon as catalyst, hydrazine hydrate as reducing agent, then reduce aromatic nitro compounds to aniline compounds. This method is green and high efficiency, and easy to be applied in industry.

8.

发明申请
PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS 审中-公开

公开(公告)号：US20180118711A1

公开(公告)日：2018-05-03

申请号：US15694342

申请日：2017-09-01

Applicant: Omeros Corporation

Inventor： Neil S. Cutshall , Jennifer Lynn Gage , Thomas Neil Wheeler

IPC: C07D401/04 , C07C251/80 , C07D295/135 , C07C243/32 , C07D333/60 , C07D319/18 , C07D317/62 , C07D295/155 , C07D275/02 , C07D265/36 , C07D257/06 , C07D249/08 , C07D249/04 , C07D235/16 , C07D231/12 , C07D215/14 , C07D213/74 , C07D213/56 , C07C255/66 , C07C251/88 , C07C251/86 , A61K31/54 , A61K31/5375 , A61K31/47 , A61K31/425 , A61K31/4196 , A61K31/4184 , A61K31/415 , A61K31/41 , A61K31/40 , A61K31/36 , A61K31/357 , A61K31/15

CPC classification number: C07D401/04 , A61K31/15 , A61K31/357 , A61K31/36 , A61K31/40 , A61K31/41 , A61K31/415 , A61K31/4184 , A61K31/4196 , A61K31/425 , A61K31/47 , A61K31/5375 , A61K31/54 , C07C243/32 , C07C251/80 , C07C251/86 , C07C251/88 , C07C255/66 , C07C2601/08 , C07D213/56 , C07D213/74 , C07D215/14 , C07D231/12 , C07D235/16 , C07D249/04 , C07D249/08 , C07D257/06 , C07D265/36 , C07D275/02 , C07D295/135 , C07D295/155 , C07D317/62 , C07D319/18 , C07D333/60

Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.